On BIIB's Tysabri and the JCV assay If the test will indeed have compelling predictive value of developing PML, it can make Tysabri the drug of choice for JCV Ab negative MS patients, imo. However, data from STRATIFY1/2 studies are 2+ years away.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.